Mohammad Ghani, MD
Allergy · Westchester, ILNPI 1194739268
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.3% of the total across 735 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 15.5% — the pattern of someone who eats at a lot of different presentations. Among allergy clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 735 payments — averaging $21.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$2K
- Sanofi$2K
- Regeneron Healthcare Solutions, Inc.$1K
- Pfizer$1K
- Novartis$772
- plus $6K from 31 others
What the payments were for
- Food & beverage$15,56097%
- Education$4403%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 96 | $2,473 |
| GSK | 117 | $2,342 |
| Sanofi | 90 | $1,987 |
| Regeneron Healthcare Solutions, Inc. | 54 | $1,399 |
| Pfizer | 60 | $1,015 |
| Novartis | 39 | $772 |
| Amgen(2 entities) | 21 | $729 |
| Mylan Specialty L.p. | 30 | $706 |
| AbbVie | 31 | $567 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $506 |
| Optinose US, Inc. | 34 | $483 |
| Teva Pharmaceuticals USA, Inc. | 21 | $480 |
| Biocryst US Sales Co., LLC | 24 | $453 |
| CSL Behring | 12 | $355 |
| Biohaven Pharmaceutical Holding Company Ltd. | 18 | $270 |
| Blueprint Medicines Corporation | 9 | $227 |
| Genentech USA, Inc. | 8 | $176 |
| Boehringer Ingelheim | 9 | $160 |
| Sanofi-aventis U.S. LLC | 2 | $160 |
| Electromed, Inc. | 9 | $143 |
| Alk-abello, Inc | 4 | $83 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $82 |
| Biohaven Pharmaceuticals, Inc. | 3 | $61 |
| Cycle Pharmaceuticals Inc | 2 | $54 |
| Aimmune Therapeutics, Inc. | 2 | $39 |
| Tactile Systems Technology Inc | 1 | $36 |
| Phadia US Inc. | 2 | $32 |
| Merck | 2 | $31 |
| Hospira, Inc. | 1 | $28 |
| Incyte Corporation | 1 | $25 |
| Lundbeck LLC | 1 | $24 |
| Viatris Specialty LLC | 1 | $22 |
| Verona Pharma, Inc. | 1 | $20 |
| Shire North American Group Inc | 1 | $20 |
| Johnson & Johnson | 1 | $13 |
| Eyevance Pharmaceuticals LLC | 1 | $13 |
| Hikma Pharmaceuticals USA | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEZSPIRE$691
- NUCALA$338
- FASENRA$243
- DUPIXENT$239
- FARXIGA$123
- CIBINQO$122
- ArmonAir Digihaler$112
- ProAir Digihaler$112
- AirDuo RespiClick$112
How this compares
$16,000 in reported general payments places this provider in the 90th percentile of 47 allergy providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FasenraBenralizumab | 11 | $62,660 |
| TezspireTezepelumab-Ekko | 12 | $48,378 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 66 | $44,731 |
| Breo ElliptaFluticasone/Vilanterol | 48 | $21,283 |
| FarxigaDapagliflozin Propanediol | 15 | $20,430 |
| JanuviaSitagliptin Phosphate | 14 | $19,081 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 13 | $6,073 |
| Arnuity ElliptaFluticasone Furoate | 17 | $5,906 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $4,783 |
| DuleraMometasone/Formoterol | 13 | $4,545 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 132 | $3,705 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 14 | $2,898 |
| Montelukast Sodium | 251 | $2,377 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 12 | $1,921 |
| Fluticasone Propionate | 75 | $1,008 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFasenra, Tezspire, Farxiga, Symbicort | $2,473 | $136,25051 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $2,342 | $71,920131 claims |
| MerckJanuvia, Dulera | $31 | $23,62627 claims |
| Boehringer IngelheimCombivent Respimat | $160 | $6,07313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 47 allergy providers in Illinois.
Other allergy in Westchester
- Ewa SchaferGlenview$165K
- Brian RotskoffChicago$82K
- Bruce BochnerChicago$43K
- Mark MillerHoffman Estates$17K
- Sai NimmagaddaOrland Park$14K
- Archana NarayanJoliet$11K
- Alan ResnickOrland Park$9K
- Alex ThomasChicago$9K
- Lee SoninSchaumburg$7K
- Renu GovindaiahSpringfield$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.